Clinical Science Director – Oncology Programs

Revolution Medicines; San Francisco (CA); On-site; USD 244,000 - 305,000; Full time

Job summary

Revolution Medicines is seeking an experienced Senior Director, Clinical Science to lead clinical development strategy for our oncology programs. You will oversee trial design, data interpretation, and regulatory interactions across CDP components, mentoring a cross-functional team and driving timelines to milestones.

The role requires a PhD or PharmD plus 10+ years in clinical development, deep knowledge of GCP/ICH, and a track record in regulatory submissions and investigator engagement.

Qualifications

• PhD or PharmD required with 10+ years in clinical development or equivalent experience.
• Experience with data analysis, interpretation and regulatory interactions.
• Strong knowledge of GCP/ICH, FDA/EMA guidelines and health authority interactions.

Responsibilities

• Lead clinical science aspects of the CDP and regulatory documentation.
• Oversee trial design, site selection, data management and safety reviews.
• Mentor and manage cross-functional clinical development teams to meet milestones.
• Engage with investigators, regulators and key stakeholders to drive program strategy.
• Drive timelines, budgets and resourcing to support multiple programs.

Skills

Clinical development

Data analysis

Trial design

Regulatory submissions

Cross-functional leadership

GCP/ICH knowledge

Regulatory strategy

Investigator engagement

Mentoring

Project management

Education

PhD, PharmD or equivalent

Job description

Revolution Medicines is seeking an experienced Senior Director, Clinical Science to lead clinical development strategy for our oncology programs. You will oversee trial design, data interpretation, and regulatory interactions across CDP components, mentoring a cross-functional team and driving timelines to milestones.

The role requires a PhD or PharmD plus 10+ years in clinical development, deep knowledge of GCP/ICH, and a track record in regulatory submissions and investigator engagement.